Korea’s Boryung Licenses Hypertension Therapy Kanarb To China’s Harbin Gloria
This article was originally published in PharmAsia News
Executive Summary
In its latest deal for the sale of its hypertension Kanarb product outside Korea, Boryung signed a 10-year deal with China from 2018.